Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Selinexor Shows Potential as Maintenance Therapy for TP53 Wild-Type, pMMR Endometrial Cancer

November 11th 2024

Debra L. Richardson, MD, FACS, FACOG, discusses how selinexor may address the need for effective maintenance therapies in pMMR, TP53 wild-type endometrial cancer.

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

November 8th 2024

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

November 7th 2024

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

November 7th 2024

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma

November 7th 2024

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

November 7th 2024

Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.

Mirdametinib May Provide Long-Awaited Treatment Alternative for Adults/Children With NF1-PNs

November 6th 2024

Angela Hirbe, MD, PhD, discusses the potential significance of MEK inhibitors such as mirdametinib for adult and pediatric patients with NF1-PN.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphoma

November 5th 2024

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

November 5th 2024

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

Ongoing Research in Orthopedic Oncology Is Revolutionizing MBD Management

November 5th 2024

R. Lor Randall, MD, FACS, discusses research in orthopedic oncology that is revolutionizing the management of metastatic bone disease from primary cancers.

Selinexor May Confer PFS Benefit in TP53 Wild-Type Endometrial Cancer

November 4th 2024

David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.

Prevention and Early Recognition of Veno-Occlusive Disease Is Key to Reducing Post-Transplant Mortality

November 1st 2024

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

Technical Advances and Efforts to Bridge Care Gaps Take Center Stage During Breast Cancer Awareness Month

October 31st 2024

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer

October 31st 2024

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

Sacituzumab Tirumotecan NDA for Pretreated EGFR+ NSCLC Accepted for Review in China

October 31st 2024

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC

October 31st 2024

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development

October 30th 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Breast Cancer Awareness Month Spotlights Progress With Personalized Medicine

October 30th 2024

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.